Therefore, we compared the efficacy of the HIF-1α inhibitor (HIF-1α-i) PX-478-2HCL to that of AsA in the IP + LC model (Fig. 3A). The gene discussed is HIF1A; the disease is laryngotracheoesophageal cleft.